NCT00451295 - A Phase III, Multi-Centre, Randomised, Placebo-Controlled Study in Combination With Ca-based P Binders in Patients With Hyperphosphatemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Chronic Kidney DiseaseDialysisHyperphosphatemia

Interventions

DRUG

MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)

3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose

DRUG

Placebo

3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose

Trial Locations (25)

Frýdek-Místek

Ostrava

Bordeaux

Montpelier

Aachen

Coburg

Lecco

Milan

Pavia

Skopje

Gdansk

Krakow

Lodz

Oświęcim

Poznan

Wejherowo

Wroclaw

Belgrade

Niš

Novisad

Cape Town

Gauteng

Barcelona

Oviedo

Stevenage